Clinical Trial Update: Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating semaglutide for polycystic ovary syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycystic Ovary Syndrome

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: Methodist Health System | Conditions: Polycystic Ovary Syndrome | Phase 1 | Status: WITHDRAWN